Taiwanese drug maker SyneuRx announced a capital increase, issuing a total of 10 million shares. The fund raised will finance clinical trials of SNB01 for COVID-19 and SND11, 12 and 13 for Schizophrenia. It is anticipated SNB01 phase II to be ‘unblinded’ and the second interim trial results of SND13 to be released towards the end of the year or early in 2022.
In addition to SyneuRx’s pipeline shown above, the company will use the fund for Pentarlandir, an oral drug to treat COVID infections, which has started its phase II trial in US since April 2021.
The fund raising was led by Taiwan Capital, Mega International Commercial Bank, SinoPac Holdings, which will connect SyneuRx with opportunities for global partnerships as well as capital market.
SyneuRx is pioneering and developing revolutionary, completely new classes of drug to answer the unmet medical needs in central nervous system (CNS) disorders. Our candidate drugs hold great promise to fast track the development process and reach a dominant position in the CNS drug market quickly. The candidates in our pipeline represent a rare opportunity with low risk and potential success.
Source in Chinese: Economic Daily